GO:1904713 beta-catenin destruction complex binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904713 beta-catenin destruction complex binding is a molecular function defined as binding to a beta-catenin destruction complex.
• The beta-catenin destruction complex is a multiprotein assembly containing APC, Axin1, GSK3B, CK1, and beta-catenin that promotes beta-catenin phosphorylation and degradation.
• Dynamic interactions within the destruction complex, including Axin-GSK3B binding, are altered by Wnt signaling in vivo.
• APC controls Wnt-induced recruitment of the destruction complex in human colonocytes, linking this binding function to colorectal cancer biology.
• Disruption of the destruction complex via Ephexin1-Axin1 interaction promotes colorectal cancer proliferation, showing disease relevance of complex binding.
• Studying GO:1904713 requires methods such as co-immunoprecipitation, proximity ligation, and CRISPR-based gene editing to dissect binding interfaces [1,2,3].
Description
GO:1904713 beta-catenin destruction complex binding is a molecular function that describes the binding of a protein or other molecule to the beta-catenin destruction complex. This complex is a central negative regulator of Wnt/beta-catenin signaling, and its assembly and interactions are critical for controlling beta-catenin levels. The destruction complex includes APC, Axin1, GSK3B, CK1, and beta-catenin, and its binding interactions determine whether beta-catenin is phosphorylated and targeted for degradation. Researchers study this term to understand how Wnt signaling is modulated and how disruption of these binding events contributes to diseases such as cancer [2,3]. The dynamic nature of the complex, including changes in Axin-GSK3B interactions upon Wnt stimulation, highlights the importance of binding events in signal transduction. In human colonocytes, APC controls the recruitment of the destruction complex in response to Wnt, further emphasizing the role of binding in cellular responses. Thus, GO:1904713 represents a key molecular function at the interface of Wnt signaling and disease.
beta-catenin destruction complex binding At A Glance
| GO ID | GO:1904713 |
|---|---|
| GO term | beta-catenin destruction complex binding |
| Ontology | molecular_function |
| Synonym | 23S APC complex binding; APC-Axin-1-beta-catenin complex binding; Axin-APC-beta-catenin-GSK3B complex binding; BDC binding; beta-catenin degradation complex binding |
| Major function | Binding to the beta-catenin destruction complex, a multiprotein assembly that promotes beta-catenin degradation |
| Complex components | APC, Axin1, GSK3B, CK1, beta-catenin |
| Related process | Wnt/beta-catenin signaling, beta-catenin phosphorylation and degradation [1,2] |
| Disease relevance | Colorectal cancer, other cancers with dysregulated Wnt signaling [3,6] |
What Is GO:1904713?
According to the Gene Ontology, GO:1904713 beta-catenin destruction complex binding is defined as binding to a beta-catenin destruction complex. This means the function is executed by a molecule that physically interacts with the multiprotein complex responsible for targeting beta-catenin for degradation. The term is a molecular function and includes synonyms such as 23S APC complex binding, APC-Axin-1-beta-catenin complex binding, Axin-APC-beta-catenin-GSK3B complex binding, BDC binding, and beta-catenin degradation complex binding.
Why Is beta-catenin destruction complex binding Important in Cell Biology?
GO:1904713 beta-catenin destruction complex binding is important because it represents a critical node in the Wnt/beta-catenin signaling pathway, which controls cell proliferation, differentiation, and stemness. Dysregulation of this binding function can lead to aberrant beta-catenin accumulation, a hallmark of many cancers, particularly colorectal cancer [3,6]. Understanding the molecular details of how proteins bind to the destruction complex can reveal new therapeutic targets and biomarkers [2,3]. Moreover, the dynamic regulation of complex interactions by Wnt ligands underscores the need to study binding events in real time and in relevant cellular contexts.
• Controls beta-catenin stability and thus Wnt signaling output.
• Mutations in APC, a core component, are frequent in colorectal cancer and affect complex binding.
• Axin1 interactions with GSK3B are dynamically regulated by Wnt signaling in vivo.
• Disruption of the complex via Ephexin1-Axin1 interaction promotes colorectal cancer proliferation.
• SP1 regulation by the destruction complex modulates Wnt response, linking binding to transcriptional control.
• Evolutionary studies reveal conserved beta-catenin recognition mechanisms in the destruction complex.
• FAT4 overexpression regulates beta-catenin/STT3/PD-L1 axis in cervical cancer, implicating complex-related binding in immune evasion.
• Targeting destruction complex binding interfaces may offer therapeutic strategies for Wnt-driven cancers [3,6].
Molecular Mechanism of beta-catenin destruction complex binding
Assembly of the destruction complex
In simple terms: The destruction complex is like a molecular machine that tags beta-catenin for disposal.
The beta-catenin destruction complex is assembled from scaffold proteins APC and Axin1, kinases GSK3B and CK1, and the substrate beta-catenin. Binding events among these components are essential for complex integrity and function. Axin1 serves as a scaffold that directly binds APC, GSK3B, CK1, and beta-catenin, facilitating phosphorylation of beta-catenin. The assembly is dynamic and can be regulated by Wnt signaling, which alters interactions such as Axin-GSK3B binding.
Beta-catenin phosphorylation and degradation
In simple terms: Once beta-catenin is bound to the complex, it gets tagged with phosphate groups, which marks it for destruction.
Within the destruction complex, CK1 and GSK3B sequentially phosphorylate beta-catenin at N-terminal residues, creating a phosphodegron recognized by beta-TrCP, leading to ubiquitination and proteasomal degradation. Binding of beta-catenin to the complex is a prerequisite for this phosphorylation. The efficiency of this process depends on the structural arrangement and binding affinities of complex components.
Regulation by Wnt signaling
In simple terms: Wnt signals can temporarily disable the destruction complex, allowing beta-catenin to accumulate.
Wnt ligands induce changes in the destruction complex that reduce its ability to bind and phosphorylate beta-catenin. In vivo studies show that Wnt signaling alters Axin-GSK3B interactions, leading to complex inactivation. APC controls Wnt-induced recruitment of the destruction complex in human colonocytes, indicating that binding events are dynamically regulated. These regulatory mechanisms ensure appropriate beta-catenin levels in response to developmental and homeostatic cues [1,2].
Accessory and regulatory proteins
In simple terms: Other proteins can interact with the destruction complex and change how it works.
Proteins such as Ephexin1 can interact with Axin1 and disrupt the destruction complex, promoting colorectal cancer proliferation. The transcription factor SP1 is regulated by the destruction complex, modulating Wnt response. Additionally, FAT4 overexpression regulates the beta-catenin/STT3/PD-L1 axis in cervical cancer, linking complex-related binding to immune regulation. These examples illustrate that GO:1904713 encompasses binding events that can have diverse functional consequences [5,6,7].
Evolutionary conservation of beta-catenin recognition
In simple terms: The way the destruction complex recognizes beta-catenin has deep evolutionary roots.
Reconstruction of the evolutionary origin of beta-catenin recognition in the Wnt destruction complex reveals conserved structural features that mediate binding. This conservation underscores the fundamental importance of GO:1904713 in metazoan biology. Comparative studies can identify key residues and interfaces that are critical for binding and regulation.
Key Genes Involved in GO:1904713 beta-catenin destruction complex binding
The following genes encode proteins that are directly involved in or regulate beta-catenin destruction complex binding (GO:1904713).
| Gene | Major Role | Research Relevance |
|---|---|---|
| APC | Scaffold protein in the destruction complex; binds beta-catenin and Axin1 | Mutations in APC are common in colorectal cancer and affect complex binding |
| AXIN1 | Scaffold protein; binds APC, GSK3B, CK1, and beta-catenin | Axin1 interactions are dynamically regulated by Wnt signaling |
| GSK3B | Kinase that phosphorylates beta-catenin within the complex | Axin-GSK3B interactions are altered by Wnt in vivo |
| CSNK1A1 | Casein kinase 1 alpha; phosphorylates beta-catenin priming for GSK3B | Part of the destruction complex; potential target for modulating Wnt signaling |
| CTNNB1 | Beta-catenin; substrate of the destruction complex | Mutations in CTNNB1 can stabilize beta-catenin and drive cancer |
| BTRC | Beta-TrCP; recognizes phosphorylated beta-catenin for ubiquitination | E3 ubiquitin ligase component; downstream of complex binding |
| EPHA4 | Ephrin receptor; may interact with Ephexin1 to affect Axin1 | Ephexin1-Axin1 interaction disrupts complex in colorectal cancer |
| SP1 | Transcription factor regulated by the destruction complex | Modulates Wnt response; links complex binding to transcription |
| FAT4 | Atypical cadherin; regulates beta-catenin/STT3/PD-L1 axis | Overexpression promotes antitumor immunity in cervical cancer |
| STT3 | Oligosaccharyltransferase subunit; part of beta-catenin/STT3/PD-L1 axis | Potential mediator of immune evasion downstream of beta-catenin |
| CD274 | PD-L1; immune checkpoint ligand regulated by beta-catenin/STT3 axis | Target for immunotherapy; linked to FAT4 overexpression |
| AXIN2 | Axin family member; may participate in destruction complex | Wnt target gene; feedback regulator of signaling |
| DVL | Dishevelled; transmits Wnt signals to destabilize destruction complex | Key upstream regulator of complex binding dynamics |
| LRP6 | Wnt co-receptor; involved in signal transduction to destruction complex | Membrane component that influences complex recruitment |
| FZD | Frizzled receptor; binds Wnt ligands | Upstream of destruction complex regulation |
| CK1 | Casein kinase 1 family; phosphorylates beta-catenin | Priming kinase in the destruction complex |
| UBB | Ubiquitin; tags beta-catenin for degradation | Downstream of complex binding and phosphorylation |
| PSMD | Proteasome subunit; degrades ubiquitinated beta-catenin | Final step in beta-catenin turnover |
How Is beta-catenin destruction complex binding Regulated?
The beta-catenin destruction complex binding function is regulated by Wnt signaling, which alters interactions within the complex, such as Axin-GSK3B binding. APC controls Wnt-induced recruitment of the destruction complex in human colonocytes. Additionally, accessory proteins like Ephexin1 can disrupt the complex by interacting with Axin1. The transcription factor SP1 is regulated by the destruction complex, providing feedback modulation. These regulatory mechanisms ensure dynamic control of beta-catenin levels in response to cellular signals [1,2,3].
beta-catenin destruction complex binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APC | Colorectal cancer; impaired destruction complex binding | APC knockout or point-mutant colon organoids |
| AXIN1 | Colorectal cancer; Ephexin1-Axin1 interaction disrupts complex | AXIN1 knockout or knock-in of binding-deficient mutants |
| CTNNB1 | Various cancers; beta-catenin stabilization | CTNNB1 point mutations (e.g., phosphorylation sites) |
| FAT4 | Cervical cancer; regulates beta-catenin/STT3/PD-L1 | FAT4 overexpression or knockout in cervical cancer cell lines |
| SP1 | Wnt response modulation | SP1 knockout or overexpression in Wnt-responsive cells |
Colorectal cancer
Dysregulation of the beta-catenin destruction complex is a hallmark of colorectal cancer. Mutations in APC, a core component, impair complex function and lead to beta-catenin accumulation. Disruption of the complex via Ephexin1-Axin1 interaction promotes colorectal cancer proliferation. These findings highlight GO:1904713 as a critical function in colorectal cancer pathogenesis [3,6].
Cervical cancer and immune evasion
FAT4 overexpression regulates the beta-catenin/STT3/PD-L1 axis in cervical cancer, linking destruction complex-related binding to antitumor immunity. This suggests that modulating complex binding could influence immune checkpoint expression and immunotherapy responses.
Wnt-related developmental disorders
Given the central role of the destruction complex in Wnt signaling, alterations in binding interactions could contribute to developmental abnormalities. However, specific disorders linked to GO:1904713 require further investigation [1,2].
From beta-catenin destruction complex binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene bind the destruction complex? | Knockout of the gene followed by co-immunoprecipitation of complex components |
| Does a specific point mutation affect binding affinity? | Point-mutation knock-in of the candidate gene |
| Does a disease-associated mutation alter complex assembly? | Knock-in of the mutation in cell lines or organoids |
| Where does the protein interact with the complex in cells? | Tagged knock-in (e.g., GFP) for imaging |
| Does overexpression of the gene disrupt complex function? | Overexpression cell models |
| Can we identify novel regulators of complex binding? | CRISPR library screening |
How to Study the beta-catenin destruction complex binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between proteins | Validate binding of candidate to destruction complex |
| Proximity ligation assay | In situ protein-protein interactions | Visualize complex binding in cells |
| Western blot | Beta-catenin phosphorylation and stability | Assess functional impact of binding |
| CRISPR knockout screen | Genes affecting complex binding or Wnt signaling | Discover novel regulators |
| Live-cell imaging | Dynamic interactions of tagged proteins | Study real-time complex assembly |
| Organoid culture | Physiological relevance in 3D tissue | Model colorectal cancer with APC mutations |
| RNA-seq | Transcriptional changes upon complex modulation | Identify downstream Wnt target genes |
| Proteomics | Global protein interactions and modifications | Map destruction complex interactome |
Co-immunoprecipitation and pull-down assays
Co-immunoprecipitation (co-IP) is a standard method to detect binding between a protein of interest and the beta-catenin destruction complex. By lysing cells and immunoprecipitating a complex component such as Axin1 or APC, researchers can assess whether the candidate protein co-purifies with the complex. This method is often used with knockout or overexpression models to validate binding.
Proximity ligation and imaging
Proximity ligation assays (PLA) and fluorescence microscopy can visualize interactions between proteins and the destruction complex in situ. These techniques provide spatial information about binding events and can be used to study dynamic changes upon Wnt stimulation. Tagged knock-in cell lines expressing fluorescently labeled complex components facilitate live-cell imaging.
CRISPR-based genetic screens
CRISPR knockout or activation screens can identify genes that regulate destruction complex binding. For example, a screen for modifiers of Wnt signaling might uncover novel binding partners or regulators. Such screens are powerful for discovering components of the GO:1904713 functional network.
Biochemical assays for beta-catenin phosphorylation
Phosphorylation of beta-catenin is a downstream readout of destruction complex binding and activity. Western blotting with phospho-specific antibodies can measure beta-catenin phosphorylation at GSK3B target sites. This assay is often used to confirm functional consequences of altered binding.
How CRISPR Can Be Used to Study GO:1904713 beta-catenin destruction complex binding
Knockout
CRISPR knockout of genes encoding destruction complex components or candidate binding partners can abolish binding and reveal functional consequences. For example, APC knockout in colonocytes leads to loss of Wnt-induced complex recruitment. Knockout models are essential for establishing causality in GO:1904713 studies [3,6].
Point Mutation
Point mutations can be introduced to disrupt specific binding interfaces without affecting overall protein stability. For instance, mutating phosphorylation sites in beta-catenin prevents its recognition by the complex. Such models help dissect the precise residues required for binding.
Knock-in
Knock-in of tagged or mutant versions of complex components allows tracking and manipulation of binding events. Tagged knock-in of Axin1 or APC enables imaging and co-IP studies. Disease-associated mutations can be knocked in to model their effects on complex binding.
Overexpression
Overexpression of candidate genes can test whether increased protein levels disrupt or enhance destruction complex binding. For example, FAT4 overexpression regulates the beta-catenin/STT3/PD-L1 axis in cervical cancer. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports beta-catenin destruction complex binding Research
Researchers studying beta-catenin destruction complex binding-related genes often need to determine whether a candidate gene is causally involved in complex assembly, regulation, or downstream signaling. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for beta-catenin destruction complex binding research.
Frequently Asked Questions About beta-catenin destruction complex binding
What is GO:1904713 beta-catenin destruction complex binding?
GO:1904713 is a Gene Ontology molecular function term defined as binding to a beta-catenin destruction complex, a multiprotein assembly that targets beta-catenin for degradation.
What genes are involved in beta-catenin destruction complex binding?
Key genes include APC, AXIN1, GSK3B, CSNK1A1, and CTNNB1, which encode core components of the destruction complex.
How is the beta-catenin destruction complex regulated?
The complex is regulated by Wnt signaling, which alters interactions such as Axin-GSK3B binding, and by accessory proteins like Ephexin1 [2,6].
What diseases are associated with beta-catenin destruction complex binding?
Colorectal cancer is strongly associated, with mutations in APC and disruption of the complex promoting tumorigenesis [3,6]. Other cancers may also involve dysregulation.
What methods are used to study beta-catenin destruction complex binding?
Common methods include co-immunoprecipitation, proximity ligation assays, Western blotting for beta-catenin phosphorylation, and CRISPR screens [1,2,6].
How does Wnt signaling affect the destruction complex?
Wnt signaling induces changes that reduce the complex's ability to bind and phosphorylate beta-catenin, leading to beta-catenin stabilization [2,3].
What is the role of APC in the destruction complex?
APC is a scaffold protein that binds beta-catenin and Axin1, and it controls Wnt-induced recruitment of the complex in colonocytes.
Can CRISPR be used to study beta-catenin destruction complex binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect binding mechanisms and functional consequences [3,6].
What are the synonyms for GO:1904713?
Synonyms include 23S APC complex binding, APC-Axin-1-beta-catenin complex binding, Axin-APC-beta-catenin-GSK3B complex binding, BDC binding, and beta-catenin degradation complex binding.
Why is beta-catenin destruction complex binding important for cancer research?
Because disruption of this binding leads to beta-catenin accumulation, which drives proliferation in cancers such as colorectal cancer [3,6].
Conclusion
GO:1904713 beta-catenin destruction complex binding is a fundamental molecular function that governs Wnt/beta-catenin signaling and is critical for tissue homeostasis. Its dysregulation is implicated in cancer and other diseases, making it a prime target for research and therapeutic intervention [1,3,6]. Advances in CRISPR-based models and biochemical assays continue to unravel the precise binding mechanisms and regulatory networks, offering new opportunities for drug discovery [2,5,7].
References
- 1. Stamos JL et al.. 2013. The β-catenin destruction complex.. Cold Spring Harb Perspect Biol 5(1):a007898 PMID: 23169527
- 2. Lybrand DB et al.. 2019. Destruction complex dynamics: Wnt/β-catenin signaling alters Axin-GSK3β interactions in vivo.. Development 146(13) PMID: 31189665
- 3. Parker TW et al.. 2020. APC controls Wnt-induced β-catenin destruction complex recruitment in human colonocytes.. Sci Rep 10(1):2957 PMID: 32076059
- 5. Wang D et al.. 2023. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.. J Exp Clin Cancer Res 42(1):222 PMID: 37658376
- 6. Kim J et al.. 2025. Disruption of the β-catenin destruction complex via Ephexin1-Axin1 interaction promotes colorectal cancer proliferation.. Exp Mol Med 57(1):151-166 PMID: 39741188
- 7. Mir R et al.. 2018. Regulation of Transcription Factor SP1 by the β-Catenin Destruction Complex Modulates Wnt Response.. Mol Cell Biol 38(22) PMID: 30181396
- 8. Sun H et al.. 2026. Reconstructing the evolutionary origin of β-catenin recognition in the Wnt destruction complex.. Mol Biol Evol 43(8) PMID: 42489500
